Following the announcement of a large layoff round in April and a major restructuring initiative unveiled earlier this month, Genentech is sending more jobs to the chopping block.

The University of California, Los Angeles (UCLA) has received a $120 million commitment to support the recently established California Institute for Immunology and Immunotherapy, positioning the university to establish research entities in Los Angeles focused on vaccine development and the microbiome.

Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases.

After postponing its U.S. plans at the top of this year, Boston Scientific has now secured an earlier-than-previously-expected European approval for its latest transcatheter aortic valve replacement implant.

Bayer executives were keen to stress to Fierce this summer that the German pharma giant’s appetite for dealmaking hasn’t been curbed by a groupwide restructuring. Its latest cancer-focused collaboration suggests Bayer has indeed retained a taste for intriguing new modalities.

Four months after Chinese gene editing company YolTech Therapeutics took its cholesterol disease-focused candidate into the clinic, Salubris Pharmaceuticals has secured the local rights to the drug for 205 million Chinese yuan ($28.7 million).

Navigator Medicines has equipped itself with $100 million in series A funds as the young biotech charts a course for its newly acquired autoimmune drugs.

The U.S. Department of Health and Human Services is sowing the seeds of advanced cancer treatment in the Prairie State. Through the Advanced Research Projects Agency for Health (ARPA-H) program, the department has granted engineering groups at the University of Illinois Urbana-Champaign two awards totaling about $54 million to develop new techniques for both studying and removing tumors.

Organ preservation and transport company Paragonix Technologies has agreed to be acquired through a $477 million deal offered by Getinge—which expects the international transplant market to continue growing by double digits and top $10 billion by 2033.